Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML).
Bcr-Abl is the predominant therapeutic target in chronic myeloid leukemia (CML), and tyrosine kinase inhibitors (TKIs) that inhibit Bcr-Abl have been successful in treating CML. With progression of CML disease especially in blast crisis stage, cells from CML patients become resistant to imatinib mesylate (IM) and other TKIs, resulting in relapse. Because Bcr-Abl is known to drive multiple signaling pathways, the study of the regulation of stability of Bcr-Abl in IM-resistant CML cells is a critical issue as a possible therapeutic strategy. Here, we report that a new dual-kinase chemical inhibitor, ON044580, induced apoptosis of Bcr-Abl+ IM-sensitive, IM-resistant cells, including the gatekeeper Bcr-Abl mutant, T315I, and also cells from blast crisis patients. In addition, IM-resistant K562-R cells, cells from blast crisis CML patients, and all IM-resistant cell lines tested had reduced ability to form colonies in soft agar in the presence of 0.5 µM ON044580. In in vitro kinase assays, ON044580 inhibited the recombinant Jak2 and Abl kinase activities when the respective Jak2 and Abl peptides were used as substrates. Incubation of the Bcr-Abl+ cells with ON044580 rapidly reduced the levels of the Bcr-Abl protein and also reduced the expression of HSP90 and its client protein levels. Lysates of Bcr-Abl+ cell lines were found to contain a large signaling network complex composed of Bcr-Abl, Jak2, HSP90, and its client proteins as detected by a gel filtration column chromatography, which was rapidly disrupted by ON044580. Therefore, targeting Jak2 and Bcr-Abl kinases is an effective way to destabilize Bcr-Abl and its network complex, which leads to the onset of apoptosis in IM-sensitive and IM-resistant Bcr-Abl+ cells. This inhibitory strategy has potential to manage all types of drug-resistant CML cells, especially at the terminal blast crisis stage of CML, where TKIs are not clinically useful.
Samanta
Ajoy K
AK
Department of Molecular Pathology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Chakraborty
Sandip N
SN
Wang
Yan
Y
Schlette
Ellen
E
Reddy
E Premkumar
EP
Arlinghaus
Ralph B
RB
Biochem J. 2005 Dec 1;392(Pt 2):335-44
16048438
Oncogene. 2009 Apr 9;28(14):1669-81
19234487
Nature. 1973 Jun 1;243(5405):290-3
4126434
Cancer Res. 2004 Jan 15;64(2):672-7
14744784
Nature. 2003 Sep 25;425(6956):407-10
14508491
Blood. 2004 Apr 15;103(8):3167-74
15070699
Biochem Pharmacol. 1998 Sep 15;56(6):675-82
9751071
Cancer Res. 1996 Aug 1;56(15):3426-30
8758906
Leukemia. 2007 Aug;21(8):1658-68
17541402
J Biol Chem. 2004 Feb 27;279(9):7576-83
14662759
Nat Rev Cancer. 2005 Oct;5(10):761-72
16175177
Br J Cancer. 2006 Oct 9;95(7):775-81
16953242
Cancer Res. 2006 Jul 1;66(13):6468-72
16818614
Expert Opin Emerg Drugs. 2002 Oct;7(2):277-88
15989551
Science. 1964 Jun 5;144(3623):1229-31
14150328
Oncogene. 2001 Sep 27;20(43):6188-95
11593427
Drug Resist Updat. 1999 Jun;2(3):165-172
11504487
Nat Rev Cancer. 2007 Jun;7(6):441-53
17522713
Blood. 2003 Jan 15;101(2):690-8
12509383
Blood. 2007 Apr 15;109(8):3207-13
17185463
Cancer Cell. 2002 Aug;2(2):117-25
12204532
Blood. 2007 Apr 15;109(8):3470-8
17202319
J Med Chem. 2005 Apr 7;48(7):2526-33
15801842
Blood. 2007 Jan 15;109(2):497-9
16990591
Blood. 2003 Jul 1;102(1):276-83
12623848
Nat Rev Cancer. 2007 May;7(5):345-56
17457302
Expert Opin Emerg Drugs. 2005 Feb;10(1):137-49
15757409
Blood. 2002 Oct 15;100(8):3041-4
12351420
Cell. 1993 Oct 8;75(1):175-85
8402896
Genes Cancer. 2010 Apr;1(4):331-45
20717479
Biochem Soc Trans. 2007 Nov;35(Pt 5):1347-51
17956348
Lancet Oncol. 2007 Mar;8(3):273-4
17329198
Pharmacol Ther. 1998 Aug;79(2):129-68
9749880
EMBO J. 2002 Nov 1;21(21):5766-74
12411494
Blood. 1999 Jun 15;93(12):4154-66
10361113
Cell Cycle. 2004 Sep;3(9):1098-100
15326368
Oncogene. 2008 Feb 14;27(8):1175-8
17724475
Expert Rev Anticancer Ther. 2007 Nov;7(11):1529-36
18020922
Blood. 2005 Feb 15;105(4):1768-76
15514006
Biopolymers. 2010 Mar;93(3):211-7
19697319
Jpn J Infect Dis. 2009 Sep;62(5):392-3
19762993
Expert Opin Biol Ther. 2002 Jan;2(1):3-24
11772336
Semin Oncol. 2003 Oct;30(5):709-16
14571418
Leukemia. 2008 Jul;22(7):1402-9
18418407
Blood. 2004 Jun 1;103(11):4010-22
14982876
Ann Oncol. 2003 Aug;14(8):1169-76
12881371
Hematology Am Soc Hematol Educ Program. 2005;:188-94
16304379
Cancer Cell. 2005 Nov;8(5):355-68
16286244
Oncogene. 2002 Oct 17;21(47):7137-46
12370803
Trends Mol Med. 2004 Jun;10(6):283-90
15177193
Cell Cycle. 2009 May 1;8(9):1338-43
19342894
Oncogene. 2008 May 8;27(21):3054-9
18037959
ChemMedChem. 2006 Dec;1(12):1331-40
17066389
EMBO J. 1994 Feb 15;13(4):764-73
8112292
Cancer Res. 2003 Nov 15;63(22):7777-84
14633703
Cancer Cell. 2003 Mar;3(3):213-7
12676580
J Clin Oncol. 2006 Nov 20;24(33):e51-2
17114651
Leukemia. 2001 Oct;15(10):1537-43
11587211
Hematology Am Soc Hematol Educ Program. 2007;:384-91
18024655
N Engl J Med. 1999 Apr 29;340(17):1330-40
10219069
Curr Mol Med. 2009 Jun;9(5):654-64
19601813
J Biol Chem. 2000 Oct 20;275(42):32499-507
10913439
Leuk Lymphoma. 2002 May;43(5):961-8
12148906